I'm not surprised ATH434 has been looked at for the use in FA, as the disease is largely due to excess iron aggregation.
I did post an article afew weeks ago where iron chelator drugs were used in multiple diseases including FA (I will attempt to find this article again).
Therefore I do not believe they are looking for their next go to possible disease treatment because the MSA trial will fail or is failing.
The trial of primates shown ATH434 reacted quick and reduced parkinson symptoms within 12wks, were other chelators seen improvements after 9months (which was also within the article I posted).
The results I found were also positive in that the ATH434 bound to labile iron exceptionally well compared to other iron chelators within the test.
Dr Stamlers comments to me were also of a positive tone, and hinting the trial was going well IMO.
If there are no positive changes from the mid open study report due this quarter (likely end of june), than I will consider pulling the plug myself, but until than I am remaining positive.
I'll go find the article
ATH Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)